SG52416A1 - Formulations containing hyaluronic acid - Google Patents
Formulations containing hyaluronic acidInfo
- Publication number
- SG52416A1 SG52416A1 SG1996004145A SG1996004145A SG52416A1 SG 52416 A1 SG52416 A1 SG 52416A1 SG 1996004145 A SG1996004145 A SG 1996004145A SG 1996004145 A SG1996004145 A SG 1996004145A SG 52416 A1 SG52416 A1 SG 52416A1
- Authority
- SG
- Singapore
- Prior art keywords
- hyaluronic acid
- formulations containing
- containing hyaluronic
- formulations
- acid
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229920002674 hyaluronan Polymers 0.000 title 1
- 229960003160 hyaluronic acid Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002061703A CA2061703C (en) | 1992-02-20 | 1992-02-20 | Formulations containing hyaluronic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG52416A1 true SG52416A1 (en) | 1998-09-28 |
Family
ID=4149316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG1996004145A SG52416A1 (en) | 1992-02-20 | 1993-02-16 | Formulations containing hyaluronic acid |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6140312A (no) |
| EP (1) | EP0626863B1 (no) |
| JP (1) | JPH07506812A (no) |
| KR (1) | KR100315371B1 (no) |
| CN (1) | CN1103219C (no) |
| AP (1) | AP475A (no) |
| AT (1) | ATE200736T1 (no) |
| AU (1) | AU3488893A (no) |
| CA (1) | CA2061703C (no) |
| CZ (1) | CZ290637B6 (no) |
| DE (1) | DE69330180T2 (no) |
| DK (1) | DK0626863T3 (no) |
| ES (1) | ES2156124T3 (no) |
| FI (1) | FI113522B (no) |
| GR (1) | GR3036164T3 (no) |
| HK (1) | HK1005983A1 (no) |
| HU (2) | HU225967B1 (no) |
| IN (5) | IN175918B (no) |
| MD (1) | MD960307A (no) |
| MX (1) | MX9300904A (no) |
| NO (1) | NO312939B1 (no) |
| NZ (2) | NZ299280A (no) |
| PL (1) | PL173211B1 (no) |
| PT (1) | PT626863E (no) |
| RO (1) | RO117499B1 (no) |
| SG (1) | SG52416A1 (no) |
| SK (1) | SK11193A3 (no) |
| WO (1) | WO1993016732A1 (no) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2122519C (en) * | 1994-04-29 | 2001-02-20 | Rudolf Edgar Dr. Falk | Cancer treatment and metastasis prevention |
| CA2130762C (en) * | 1994-08-24 | 1999-07-06 | Eva Anne Turley | Treatment of disease and conditions associated with macrophage infiltration |
| AU3239895A (en) * | 1994-08-10 | 1996-03-07 | Roderick T. Coward | Method of using hyaluronic acid for the detection, location and diagnosis of tumors |
| AU3159595A (en) * | 1994-08-30 | 1996-03-22 | Hyal Pharmaceutical Corporation | Hyaluronic acid and derivatives for modulation of cellular activity |
| JP4010574B2 (ja) * | 1994-12-05 | 2007-11-21 | 電気化学工業株式会社 | 皮膚外用剤 |
| US5626838A (en) * | 1995-03-13 | 1997-05-06 | The Procter & Gamble Company | Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx |
| CA2154103C (en) * | 1995-07-18 | 1998-02-24 | Samuel Simon Asculai | Treatment of mucous membrane disease, trauma or condition and for the relief of pain |
| US6875753B1 (en) | 1996-03-14 | 2005-04-05 | The Governors Of The University Of Alberta | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
| US5939047A (en) * | 1996-04-16 | 1999-08-17 | Jernberg; Gary R. | Local delivery of chemotherapeutic agents for treatment of periodontal disease |
| WO1998013024A2 (en) | 1996-09-27 | 1998-04-02 | Hyal Pharmaceutical Corporation | Hyaluronic drug delivery system |
| DE69828193T2 (de) * | 1997-10-31 | 2005-12-01 | The Board Of Regents Of The University Of Oklahoma, Norman | Hyaluronan synthase gen und seine verwendung |
| CN101275143A (zh) * | 1998-04-02 | 2008-10-01 | 俄克拉何马大学董事会 | 编码透明质酸合酶的核酸及其应用方法 |
| US6689349B1 (en) * | 1998-12-23 | 2004-02-10 | Esparma Gmbh | Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis |
| DE60036915T2 (de) | 1999-01-13 | 2008-08-07 | Alchemia Oncology Pty Ltd., Hawthorn | Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln |
| AUPQ879500A0 (en) | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
| US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
| US6828308B2 (en) * | 2000-07-28 | 2004-12-07 | Sinclair Pharmaceuticals, Ltd. | Compositions and methods for the treatment or prevention of inflammation |
| US6576226B1 (en) | 2000-11-17 | 2003-06-10 | Gary R. Jernberg | Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease |
| US6726898B2 (en) | 2000-11-17 | 2004-04-27 | Gary R. Jernberg | Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease |
| ES2607802T3 (es) | 2001-08-14 | 2017-04-04 | Tel Aviv University Future Technology Development L.P. | Partículas lipidadas de glicosaminoglicano y su uso en el suministro de fármacos y genes para diagnóstico y terapia |
| US20030143165A1 (en) * | 2002-01-25 | 2003-07-31 | Allan Evans | NSAID-containing topical formulations that demonstrate chemopreventive activity |
| US7622117B2 (en) | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
| US20050142208A1 (en) | 2002-05-09 | 2005-06-30 | Won Min Yoo | Pharmceutical composition for treatment of wounds conntaining blood plasma or serum |
| EP1569616A2 (en) * | 2002-12-04 | 2005-09-07 | Technologies Biolactis Inc. | An exopolysaccharides delivery system for active molecules |
| RU2390529C2 (ru) * | 2004-01-07 | 2010-05-27 | Сейкагаку Корпорейшн | Производное гиалуроновой кислоты и содержащее его лекарственное средство |
| FR2865651B1 (fr) * | 2004-01-29 | 2007-09-28 | Fabre Pierre Dermo Cosmetique | Compositions topiques associant des fragments de hyaluronate de sodium et un retinoide utiles en dermatologie cosmetique et medicale |
| US20050266064A1 (en) * | 2004-05-29 | 2005-12-01 | Mccarthy Kathryn J | Cosmetic compositions and methods |
| CA2616607C (en) | 2005-07-27 | 2015-06-02 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
| US7323184B2 (en) | 2005-08-22 | 2008-01-29 | Healagenics, Inc. | Compositions and methods for the treatment of wounds and the reduction of scar formation |
| WO2007028196A1 (en) | 2005-09-07 | 2007-03-15 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
| WO2007103687A2 (en) * | 2006-03-01 | 2007-09-13 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
| EP2063859B1 (en) | 2006-09-13 | 2017-01-18 | Enhance Skin Products Inc. | Cosmetic composition for the treatment of skin and methods thereof |
| US20080154241A1 (en) * | 2006-12-07 | 2008-06-26 | Burkstrand Michael J | Latent stabilization of bioactive agents releasable from implantable medical articles |
| ITMI20071267A1 (it) * | 2007-06-22 | 2008-12-23 | Fidia Farmaceutici | Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative |
| GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
| ITMI20110644A1 (it) * | 2011-04-14 | 2012-10-15 | Giuliani Spa | Sistema per il rilascio prolungato di agenti cosmetici |
| CA2868238A1 (en) | 2012-04-18 | 2013-10-24 | Ramot At Tel Aviv University Ltd. | Lipidated glycosaminoglycan particles for the delivery of nucleic acids |
| FR2994846B1 (fr) | 2012-08-29 | 2014-12-26 | Vivacy Lab | Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium |
| KR101439032B1 (ko) * | 2013-06-13 | 2014-09-05 | 동아에스티 주식회사 | 피록시캄과 히알루론산을 포함하는 골관절염 치료를 위한 액상 조성물 |
| WO2015198326A1 (en) | 2014-06-26 | 2015-12-30 | Ramot At Tel-Aviv University Ltd. | Liposomal formulations for delivery of nucleic acids |
| ME03806B (me) | 2014-11-21 | 2021-04-20 | Bristol Myers Squibb Co | Antitela protiv cd73 i njihova upotreba |
| DE202016008638U1 (de) * | 2015-09-04 | 2018-10-01 | Elena Poli | Medizinische Vorrichtung zur Behandlung von HPV-Hautinfektionen |
| CN109965104A (zh) * | 2019-03-29 | 2019-07-05 | 华熙生物科技股份有限公司 | 一种含透明质酸钠的组合物及其制备方法和应用 |
| CN115397458B (zh) * | 2020-02-25 | 2024-09-13 | 安普力菲卡控股集团公司 | 用于刺激毛发生长的组合物和方法 |
| KR102368100B1 (ko) | 2020-07-20 | 2022-02-25 | 영인기술(주) | 변압기용 단자 조립 어셈블리 |
| CN112587475B (zh) * | 2020-12-18 | 2022-09-13 | 华熙生物科技股份有限公司 | 一种载药凝胶及其制备方法 |
| KR20240133242A (ko) | 2023-02-28 | 2024-09-04 | 영인에너지솔루션 주식회사 | 변압기의 혼촉 및 방전 방지용 단자 어셈블리 |
| CN117304368B (zh) * | 2023-11-29 | 2024-03-01 | 杭州湃肽生化科技有限公司 | 一种透明质酸钠与胶原五肽的组合物及其应用 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2583096A (en) * | 1949-01-15 | 1952-01-22 | Searle & Co | Process for the production of high viscosity hyaluronic acid |
| GB769287A (en) | 1954-08-18 | 1957-03-06 | American Home Prod | Preparation of partially depolymerized hyaluronic acid and therapeutic compositions thereof |
| GB818336A (en) | 1956-06-22 | 1959-08-12 | Erba Carlo Spa | A new acid aminopolysaccharide and a process for the production thereof |
| US3042667A (en) * | 1959-03-10 | 1962-07-03 | Pharmacia Ab | Process for producing dextran derivatives and products resulting therefrom |
| FR1425265A (fr) * | 1962-05-14 | 1966-01-24 | Parke Davis & Co | Procédé de préparation d'un nouveau polysaccharide et de ses sels |
| NL123338C (no) * | 1961-12-08 | |||
| FR3715M (fr) * | 1964-06-11 | 1965-11-29 | Lucien Nouvel | Antithermiques et antirhumatismaux améliorés. |
| US3357784A (en) * | 1964-09-30 | 1967-12-12 | Kendall & Co | Exposure to intense ultraviolet light to improve characteristics of cellulosic fabrics in divinyl sulfone and glyoxal cross-linking processes |
| AT252264B (de) * | 1965-03-17 | 1967-02-10 | Etapharm Chem Pharm Lab Ges M | Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates |
| US3887703A (en) * | 1967-03-24 | 1975-06-03 | Oreal | Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions |
| US3792164A (en) * | 1970-03-31 | 1974-02-12 | Chemway Corp | Ophthalmic composition comprising water-soluble alkaloid salts of polyuronic acids |
| GB1283892A (en) | 1970-06-08 | 1972-08-02 | Irwin Irville Lubowe | Improvements in and relating to medicinal compositions for application to the skin and/or hair |
| US3845201A (en) * | 1972-04-24 | 1974-10-29 | S Loucas | Solid state ophthalmic medication delivery method |
| US3870791A (en) * | 1972-04-24 | 1975-03-11 | Heskel M Haddad | Solid state ophthalmic medication delivery method |
| DE2364373A1 (de) * | 1973-12-22 | 1975-07-10 | Hahn Carl Dr Gmbh | Pharmazeutische und kosmetische praeparate zur aeusserlichen anwendung |
| US4003991A (en) * | 1974-08-27 | 1977-01-18 | National Patent Development Corporation | Ophthalmic formulation |
| US4280954A (en) * | 1975-07-15 | 1981-07-28 | Massachusetts Institute Of Technology | Crosslinked collagen-mucopolysaccharide composite materials |
| GB1515963A (en) * | 1975-07-15 | 1978-06-28 | Massachusetts Inst Technology | Crosslinked collagen-mucopolysaccharide composite materials |
| US4045558A (en) * | 1975-10-08 | 1977-08-30 | Merck & Co., Inc. | Pilocarpine salts |
| US4141973A (en) * | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
| US4061722A (en) * | 1976-04-26 | 1977-12-06 | Interx Research Corporation | Selected quaternary ammonium salts of pilocarpine useful in reducing intraocular pressure in warm-blooded animals |
| US4470975A (en) * | 1977-10-21 | 1984-09-11 | The Johns Hopkins University | Method and composition for the elimination of water from an animal body |
| US4271143A (en) * | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
| FR2478646A2 (fr) * | 1980-03-20 | 1981-09-25 | Choay Sa | Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir |
| US4255415A (en) * | 1978-11-22 | 1981-03-10 | Schering Corporation | Polyvinyl alcohol ophthalmic gel |
| US4240163A (en) * | 1979-01-31 | 1980-12-23 | Galin Miles A | Medicament coated intraocular lens |
| US4272522A (en) * | 1979-10-15 | 1981-06-09 | Balazs Endre A | Method for stimulating phagocytic activity and synergistic compositions therefor |
| US4303676A (en) | 1980-03-21 | 1981-12-01 | Balazs Endre A | Hyaluronate based compositions and cosmetic formulations containing same |
| US4328803B1 (en) * | 1980-10-20 | 1994-01-11 | Opthalmic Systems, Inc. | Opthalmological procedures |
| JPS57185208A (en) * | 1981-05-07 | 1982-11-15 | Shiseido Co Ltd | Skin cosmetic |
| EP0066283B1 (en) * | 1981-06-02 | 1986-09-10 | Eupan Corporation | Eustatic composition for nonspecifically facilitating and amplifying the generalized homeostatic regulation and maintenance, compensation and repair in living organisms |
| US4684627A (en) * | 1981-09-08 | 1987-08-04 | Leveen Harry H | Treatment of cancer with phlorizin and its derivatives |
| JPS58183611A (ja) * | 1982-04-19 | 1983-10-26 | Kanebo Ltd | 多相乳化型化粧料 |
| JPS58183938A (ja) * | 1982-04-21 | 1983-10-27 | Shiseido Co Ltd | 乳化組成物 |
| JPS5925311A (ja) * | 1982-07-29 | 1984-02-09 | Shiseido Co Ltd | 化粧料 |
| US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| IT1229075B (it) * | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
| US4517295A (en) * | 1983-02-18 | 1985-05-14 | Diagnostic, Inc. | Hyaluronic acid from bacterial culture |
| US4478822A (en) * | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| JPS59219209A (ja) * | 1983-05-28 | 1984-12-10 | Kanebo Ltd | 皮膚化粧料 |
| AU555747B2 (en) * | 1983-08-09 | 1986-10-09 | Cilco Inc. | Chondroitin sulfate and sodium hyaluronate composition |
| IN163192B (no) * | 1983-10-11 | 1988-08-20 | Fidia Spa | |
| US4855134A (en) * | 1983-10-14 | 1989-08-08 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release preparation |
| DE3486029T2 (de) * | 1983-10-14 | 1993-05-13 | Sumitomo Pharma | Ifn-praeparat mit verzoegerter abgabe fuer parentale verabreichung. |
| NO161573C (no) * | 1983-11-25 | 1989-08-30 | Miles Inc | Fremgangsmaate til fremstilling av hyaluronsyre. |
| US4487865A (en) * | 1983-12-15 | 1984-12-11 | Biomatrix, Inc. | Polymeric articles modified with hyaluronate |
| US4500676A (en) * | 1983-12-15 | 1985-02-19 | Biomatrix, Inc. | Hyaluronate modified polymeric articles |
| US4716224A (en) * | 1984-05-04 | 1987-12-29 | Seikagaku Kogyo Co. Ltd. | Crosslinked hyaluronic acid and its use |
| US4629623A (en) * | 1984-06-11 | 1986-12-16 | Biomatrix, Inc. | Hyaluronate-poly (ethylene oxide) compositions and cosmetic formulations thereof |
| US4711780A (en) * | 1984-06-11 | 1987-12-08 | Fahim Mostafa S | Composition and process for promoting epithelial regeneration |
| US4863907A (en) * | 1984-06-29 | 1989-09-05 | Seikagaku Kogyo Co., Ltd. | Crosslinked glycosaminoglycans and their use |
| JPS6156114A (ja) * | 1984-08-27 | 1986-03-20 | Kanebo Ltd | 皮膚老化防止用化粧料 |
| JPS6164701A (ja) * | 1984-09-06 | 1986-04-03 | Meito Sangyo Kk | カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用 |
| JPS61106602A (ja) * | 1984-10-31 | 1986-05-24 | Meito Sangyo Kk | カチオン性デキストラン誘導体の高分子電解質錯体及びその利用 |
| US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US4636524A (en) * | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US4784990A (en) * | 1985-01-18 | 1988-11-15 | Bio-Technology General Corporation | High molecular weight sodium hyaluronate |
| US4713448A (en) * | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
| SE8501723L (sv) * | 1985-04-09 | 1986-10-10 | Pharmacia Ab | Preparation att anvendas vid behandling av ledinflammation |
| US4725585A (en) * | 1985-04-26 | 1988-02-16 | Pharmacia Ab | Method of enhancing the host defense |
| EP0207638B1 (en) * | 1985-06-04 | 1990-12-19 | Teijin Limited | Sustained-release pharmaceutical preparation |
| US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| US4820732A (en) * | 1985-10-04 | 1989-04-11 | The Upjohn Company | Method and compositions for reducing dysfunction in angioplasty procedures |
| SE449003B (sv) * | 1985-10-18 | 1987-03-30 | Pharmacia Ab | Sett att in vitro avskilja spermier med egen rorelseformaga medelst penetrationsmedium i vilket ingar hyaluronsyrasalt |
| IN166447B (no) * | 1985-11-27 | 1990-05-12 | Ethicon Inc | |
| EP0224987B1 (en) * | 1985-11-29 | 1992-04-15 | Biomatrix, Inc. | Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same |
| US4912093A (en) * | 1986-10-01 | 1990-03-27 | Marion Laboratories, Inc. | Use of synthetic sulfated saccharides to enhance wound healing |
| US4746504A (en) * | 1986-03-14 | 1988-05-24 | Bio-Technology General Corp. | Heavy metal salts of hyaluronic acid and their use as antimicrobial agents |
| US4784991A (en) * | 1986-03-14 | 1988-11-15 | Bio-Technology General Corp. | Heavy metal salts of hyaluronic acid and their use as antimicrobial agents |
| DE3610037A1 (de) * | 1986-03-21 | 1987-09-24 | Schering Ag | Nifedipinkombinationspraeparat |
| EP0240098A3 (en) * | 1986-04-04 | 1989-05-10 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Oligo and polysaccharides for the treatment of diseases caused by retroviruses |
| EP0244178A3 (en) * | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraocular dosage compositions and method of use |
| US4808576A (en) * | 1986-04-28 | 1989-02-28 | Mobay Corporation | Remote administration of hyaluronic acid to mammals |
| US4946870A (en) * | 1986-06-06 | 1990-08-07 | Union Carbide Chemicals And Plastics Company Inc. | Delivery systems for pharmaceutical or therapeutic actives |
| SE452469B (sv) * | 1986-06-18 | 1987-11-30 | Pharmacia Ab | Material bestaende av en tverbunden karboxylgrupphaltig polysackarid och forfarande vid framstellning av detsamma |
| US4877619A (en) * | 1986-08-25 | 1989-10-31 | Vestar, Inc. | Liposomal vesicles for intraperitoneal administration of therapeutic agents |
| JPH0725689B2 (ja) * | 1986-10-07 | 1995-03-22 | 中外製薬株式会社 | 顆粒球コロニ−刺激因子を含有する徐放性製剤 |
| IT1198449B (it) * | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
| US4879282A (en) * | 1987-03-17 | 1989-11-07 | Saliba Jr Michael J | Medical application for heparin and related molecules |
| CA1327354C (en) * | 1987-03-19 | 1994-03-01 | David Cullis-Hill | Anti-inflamatory compounds and compositions |
| US4795741A (en) * | 1987-05-06 | 1989-01-03 | Biomatrix, Inc. | Compositions for therapeutic percutaneous embolization and the use thereof |
| GB8713662D0 (en) * | 1987-06-11 | 1987-07-15 | Skandigen Ab | Hyaluronic acid derivatives |
| US4944941A (en) * | 1987-08-07 | 1990-07-31 | Genentech, Inc. | Methods and compositions for the treatment of lung conditions |
| US4900550A (en) * | 1987-08-19 | 1990-02-13 | Amy Allene Cosmetiques, Inc. | Skin care cosmetic regime |
| US4937270A (en) * | 1987-09-18 | 1990-06-26 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
| US4913898A (en) * | 1988-04-06 | 1990-04-03 | Altobella Hair Products Inc. | Hair treatment composition and method |
| IT1219587B (it) * | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | Polisaccaridi carbossiilici autoreticolati |
| CA2004740A1 (en) * | 1988-12-07 | 1990-06-07 | Cary Linsky | Low molecular weight heparin, heparinoid and hexuronyl hexosaminoglycan sulfate containing adhesion prevention barrier and process |
| CA2006060A1 (en) * | 1988-12-20 | 1990-06-20 | Michael D. Pierschbacher | Polypeptide-polymer conjugates active in wound healing |
| DE3900198A1 (de) * | 1989-01-05 | 1990-07-12 | Merck Patent Gmbh | Topisch anwendbare pharmazeutische zubereitung |
| JPH0341033A (ja) * | 1989-07-07 | 1991-02-21 | Kyowa Hakko Kogyo Co Ltd | 安定なモチリン類含有製剤 |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| US5095037B1 (en) * | 1989-12-21 | 1995-12-19 | Nissho Kk | Combined anti-inflammatory agent |
| US5092841A (en) * | 1990-05-17 | 1992-03-03 | Wayne State University | Method for treating an arterial wall injured during angioplasty |
| US5116864A (en) * | 1991-04-09 | 1992-05-26 | Indiana University Foundation | Method for preventing restenosis following reconfiguration of body vessels |
| US5116331A (en) * | 1991-04-23 | 1992-05-26 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Pressure transducer and system for cryogenic environments |
-
1992
- 1992-02-20 CA CA002061703A patent/CA2061703C/en not_active Expired - Lifetime
-
1993
- 1993-02-16 PT PT93903754T patent/PT626863E/pt unknown
- 1993-02-16 PL PL93301149A patent/PL173211B1/pl unknown
- 1993-02-16 JP JP5514407A patent/JPH07506812A/ja active Pending
- 1993-02-16 HU HU9303282A patent/HU225967B1/hu unknown
- 1993-02-16 WO PCT/CA1993/000061 patent/WO1993016732A1/en active IP Right Grant
- 1993-02-16 EP EP93903754A patent/EP0626863B1/en not_active Expired - Lifetime
- 1993-02-16 ES ES93903754T patent/ES2156124T3/es not_active Expired - Lifetime
- 1993-02-16 SG SG1996004145A patent/SG52416A1/en unknown
- 1993-02-16 MD MD96-0307A patent/MD960307A/ro not_active Application Discontinuation
- 1993-02-16 DE DE69330180T patent/DE69330180T2/de not_active Expired - Lifetime
- 1993-02-16 AU AU34888/93A patent/AU3488893A/en not_active Abandoned
- 1993-02-16 RO RO94-01388A patent/RO117499B1/ro unknown
- 1993-02-16 DK DK93903754T patent/DK0626863T3/da active
- 1993-02-16 NZ NZ299280A patent/NZ299280A/en not_active IP Right Cessation
- 1993-02-16 IN IN94CA1993 patent/IN175918B/en unknown
- 1993-02-16 AT AT93903754T patent/ATE200736T1/de active
- 1993-02-16 NZ NZ249071A patent/NZ249071A/en not_active IP Right Cessation
- 1993-02-18 CZ CZ1993230A patent/CZ290637B6/cs not_active IP Right Cessation
- 1993-02-19 AP APAP/P/1993/000491A patent/AP475A/en active
- 1993-02-19 MX MX9300904A patent/MX9300904A/es unknown
- 1993-02-20 CN CN93103488A patent/CN1103219C/zh not_active Expired - Lifetime
- 1993-05-05 SK SK11193A patent/SK11193A3/sk unknown
-
1994
- 1994-08-17 FI FI943789A patent/FI113522B/fi not_active IP Right Cessation
- 1994-08-17 NO NO19943044A patent/NO312939B1/no not_active IP Right Cessation
- 1994-08-19 KR KR1019940702859A patent/KR100315371B1/ko not_active IP Right Cessation
-
1995
- 1995-03-13 IN IN270CA1995 patent/IN182267B/en unknown
- 1995-03-13 IN IN272CA1995 patent/IN179130B/en unknown
- 1995-03-13 IN IN271CA1995 patent/IN182348B/en unknown
- 1995-03-14 IN IN293CA1995 patent/IN178280B/en unknown
- 1995-06-06 US US08/466,714 patent/US6140312A/en not_active Expired - Lifetime
- 1995-06-30 HU HU95P/P00652P patent/HU211823A9/hu unknown
-
1998
- 1998-06-10 HK HK98105085A patent/HK1005983A1/xx not_active IP Right Cessation
-
2001
- 2001-07-02 GR GR20010401015T patent/GR3036164T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP9300491A0 (en) | Formulations containing hyaluronic acid | |
| GB9209078D0 (en) | Pharmaceutical compositions | |
| ZA93190B (en) | Benzofuranyl- and thiophenylmethylthio-alkanecarboxylic acid derivatives | |
| EP0587047A3 (en) | Gestagenes containing pharmaceutical composition | |
| GB9214390D0 (en) | Formulations | |
| GB9209874D0 (en) | Pharmaceutical compositions | |
| GB2271929B (en) | Compositions containing Tarchonanthus camphoratus | |
| GB9201639D0 (en) | Pharmaceutical formulations | |
| ZA937714B (en) | Novel formulation | |
| ZA931367B (en) | Sulphonylbenzyl-substituted imidazolylpropenoic acid derivatives | |
| ZA935119B (en) | Medicinal composition comprising TCF-II | |
| ZA93125B (en) | Quinolone- and naphthyridone-carboxylic acid derivatives | |
| IL104796A0 (en) | Formulations containing hyaluronic acid | |
| GB9213271D0 (en) | Formulations | |
| GB9205739D0 (en) | Formulations | |
| GB9202474D0 (en) | Formulations | |
| GB9205738D0 (en) | Formulations | |
| GB9224539D0 (en) | Formulations | |
| GB9204898D0 (en) | Liquid formulations | |
| GB2268178B (en) | Camphyl phosphonic acid | |
| GB9212757D0 (en) | Novel formulation | |
| GB9212711D0 (en) | Novel formulation | |
| GB9216361D0 (en) | Novel formulation | |
| GB9203212D0 (en) | Pharmaceutical formulations | |
| GB9204774D0 (en) | Pharmaceutical formulations |